Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

144 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-08-31

Study Completion Date

2007-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2 phases), addition of amlodipine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

NCT00872586

Essential Hypertension

COMPLETED PHASE3

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

NCT00412932

Hypertension

COMPLETED PHASE4

Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

NCT00796159

Hypertension

COMPLETED

A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension

NCT00430638

Hypertension

COMPLETED PHASE4

Olmesartan in Essential Hypertension

NCT00185172

Essential Hypertension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Essential Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Group Type EXPERIMENTAL

olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary

Intervention Type DRUG

olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary

olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stage 1 and 2 hypertension without treatment for at least 2 weeks
* Women with no risk of becoming pregnant

Exclusion Criteria

* Study participation could result in risk to health of subject
* Cardiovascular disease
* Secondary hypertension or stage 3 hypertension
* Myocardial infarction within the last 6 months
* Congestive heart failure
* Pulmonary edema
* Valvular alterations or rheumatic cardiopathy
* Clinically relevant conduction disorders significant arrhythmias
* Alcohol or illicit drug use
* Medication abuse
* Pregnant or nursing women

Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No